NeuBase Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

NeuBase Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.1%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.1%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

May 12

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Jan 24

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Oct 02

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Jun 02

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Feb 23

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

Jan 19

NeuBase Therapeutics EPS in-line

Dec 23

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Dec 16

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

Dec 15

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NBSE şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NBSE şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

NeuBase Therapeutics Piyasaya Karşı Temettü Getirisi

NBSE temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NBSE)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (NBSE) (3 yıla kadar)	n/a

Önemli Temettü: NBSE şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NBSE şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NBSE şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NBSE herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

NeuBase Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

NeuBase Therapeutics Files Form 15

NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from S&P TMI Index

New major risk - Financial data availability

The Nasdaq Stock Market LLC Notifies NeuBase Therapeutics Regarding Non-Compliance with the Minimum Bid Price Requirement and Ineligible for a Second 180 Calendar Day Period to Regain Compliance

NeuBase Therapeutics, Inc. Announces CEO Changes

New minor risk - Financial data availability

NeuBase Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Neubase Therapeutics, Inc. Announces Franklyn G. Prendergast Board of Directors Passed Away

New major risk - Shareholder dilution

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 28, 2023

High number of new and inexperienced directors

NeuBase Therapeutics, Inc. announced that it has received $3.512751 million in funding

NeuBase Therapeutics, Inc. Presents Non-Human Primate Data Illustrating Stealth Editors Are Non-Immunogenic, Opening the Door to Redosing

Neubase Therapeutics, Inc. Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors

NeuBase Therapeutics, Inc. Announces Resignation of Eric J. Ende as Board of Director

NeuBase Therapeutics, Inc. Announces Formation of Gene Editing Advisory Board

Price target decreased to US$10.00

NeuBase Therapeutics, Inc. Announces Resignation of William Mann as President and Chief Operating Officer, Effective October 31, 2022

NeuBase Therapeutics, Inc. to Reduces its Workforce by Approximately 60%

NeuBase Therapeutics, Inc. Announces Executive Changes

Price target decreased to US$10.67

NeuBase Therapeutics Receives Non-Compliance Letter from Nasdaq

Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04

NeuBase Therapeutics, Inc., Annual General Meeting, Sep 08, 2022

NeuBase Therapeutics, Inc. Announces Promotion of William Mann to President

NeuBase Therapeutics promotes Dr. William Mann to President and COO

NeuBase Therapeutics, Inc. Presents New Preclinical Data At ASGCT 2022 for Its Dm1 Program Demonstrating Wide Tissue Distribution and Supporting Differentiated Whole-Body Treatment Solution

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

Price target decreased to US$14.67

High number of new and inexperienced directors

Price target decreased to US$14.67

Price target decreased to US$15.50

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

CFO, Treasurer & Secretary Samuel Backenroth has left the company

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from Russell 3000E Index

NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Independent Director has left the company

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Price target raised to US$17.00

New 90-day high: US$11.66

New 90-day high: US$10.08

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

New 90-day low: US$7.27

NeuBase Therapeutics EPS in-line

NeuBase Therapeutics Announces Positive Preclinical in Vivo Data for Patrol Enabled Anti-Gene for the Treatment of Myotonic Dystrophy Type 1

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

NeuBase Therapeutics Announces Appointment of Curt Bradshaw as Chief Scientific Officer

NeuBase Therapeutics Announces Addition of Eriks Rozners and Randy Davis to Scientific Advisory Board

NeuBase Therapeutics, Inc. Announces Addition of Peter Nielsen, Ph.D., Inventor of Peptide Nucleic Acid Technology, to Scientific Advisory Board

NeuBase Therapeutics, Inc. Enters into Lease Agreement with 350 Technology Drive Partners, LLC

New 90-day low - US$7.46

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin